We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Breast Cancer May Be Included in Expanded Vaccine Clinical Trials

By LabMedica International staff writers
Posted on 03 Aug 2009
A therapeutic vaccine already under phase III clinical trials for use against lung cancer and melanoma may also be effective for treating particularly aggressive and drug-resistant forms of breast cancer.

Investigators from the Ludwig Institute for Cancer Research (New York, NY, USA) used signature-sequencing data, together with nine publicly available gene expression datasets to analyze and compare the activity of CT-X genes in 1,600 breast cancer samples. More...
They reported in the July 27, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that about 50% of primary ER- (estrogen receptor)-negative and triple-negative (lacking estrogen, progesterone, and HER2 receptors) breast cancers expressed members of either or both the MAGEA and NY-ESO-1/CTAG1B families of CT-X genes. These tumors have a generally poor prognosis and few therapy options.

A major improvement in the dismal prospect for this population of breast cancer patients may rest with GlaxoSmithKline (Uxbridge, UK), which licensed MAGEA3 and NY-ESO-1 from the Ludwig Institute for Cancer Research and is currently conducting phase III clinical trials of a MAGEA3-based cancer vaccine in nonsmall cell lung cancer and melanoma.

Clinical trials may soon be extended to breast cancer, according to contributing author Dr. Andrew Simpson, scientific director of the Ludwig Institute for Cancer Research. "Vaccines targeting MAGEA3 are already in phase III trials and collaborative studies have demonstrated the safety of different forms of the NY-ESO-1 antigen in phase I and II trials in a variety of tumor types.”

Related Links:

Ludwig Institute for Cancer Research
GlaxoSmithKline



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.